Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 2 clinical study titled A Prospective, Randomized, Open-Label Phase 2 Study to Evaluate the Superiority of Inotuzumab Ozogamicin Monotherapy Versus ALLR3 for Induction Treatment of Childhood High Risk First Relapse B-Cell Precursor Acute Lymphoblastic Leukemia. The study aims to assess the effectiveness and safety of Inotuzumab Ozogamicin (InO) compared to the ALLR3 regimen in children aged 1 to under 18 years with high-risk first relapse of B-cell precursor acute lymphoblastic leukemia (ALL). This research is significant as it explores potential advancements in treatment options for this vulnerable patient group.
The study tests two interventions: Inotuzumab Ozogamicin, an experimental drug targeting CD22-positive cells, and ALLR3, an established chemotherapy regimen. InO is administered as a single course of three doses, while ALLR3 involves a combination of drugs given over several days.
This interventional study employs a randomized, parallel design with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned in a 2:1 ratio to receive either InO or ALLR3, with approximately 100 children expected to be enrolled.
The study began on May 17, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 11, 2025. These timelines are crucial for tracking the study’s progress and potential availability of results.
The outcome of this study could influence Pfizer’s stock performance and investor sentiment, particularly if InO proves more effective than current treatments. This could position Pfizer favorably in the competitive oncology market, potentially impacting other companies developing similar therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.